| Medical Condition | Heart Failure |
|---|---|
| Facility/Clinic | 1202 Medical Center Dr |
| Description | A Phase III, Double-blind, Randomized, Parallel-group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Symptomatic Chronic Heart Failure (HF: NYHA II-IV) and Left Ventricular Ejection Fraction (LVEF) < 40% We are looking for people who: · Are 18 years of age or older · Have diagnosed HF (NYHA classes II to IV) with LVEF less than 40% · Have had diagnosed chronic HF for at least 3 months · Have elevated NT-proBNP · Are NOT taking MRA Additional criteria apply, which the study team will be happy to discuss with you. Call 910-362-4040 or email byoppchester@wilmingtonhealth.com for more information. |
The team at WH Research can guide interested clinical research participants through the process of enrolling in a trial.
Please call 910-362-4040 between the hours of 8am-5pm for general research questions.